Patents Examined by Parithosh K. Tungaturthi
-
Patent number: 7202346Abstract: The present invention relates to antibodies, antibody fragments, conjugates of antibodies and antibody fragments with cytotoxic agents, and hybridomas producing the antibodies and antibody fragments, where the antibodies and antibody fragments recognize extracellular epitopes of plasma membrane proteins that are not released into the extracellular fluid, and to methods for the detection, monitoring and treatment of malignancies such as breast cancer and ovarian cancer using the antibodies, antibody fragments and conjugates.Type: GrantFiled: July 3, 2003Date of Patent: April 10, 2007Assignee: Immunogen Inc.Inventors: Gillian Payne, Thomas Chittenden, Viktor Goldmakher, Philip Chun, Kristin Sneider-Mulready, Carol A. Vater
-
Patent number: 7189816Abstract: An antibody, or a derivate or a fragment thereof, having a binding structure for a target structure is described. The antibody is displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells. Said binding structure comprises the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23–33 (CDR1), 49–55 (CDR2), 88–98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158–162 (CDR1), 177–193 (CDR2, 226–238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties. There is also described a target structure displayed in, or on the surface of tumour cells, vaccine compositions, pharmaceutical compositions as well as methods related to human malignant diseases.Type: GrantFiled: October 26, 2000Date of Patent: March 13, 2007Assignee: Active Biotech ABInventors: Thomas Brodin, Pia J. Karlström, Lennart G. Ohlsson, Jesper M. Tordsson, Philip P. Kearney, Bo H. K. Nilson
-
Patent number: 7179595Abstract: The present invention provides non-single-chain antigen-binding units that is stabilized by leucine zipper sequences. The experimental design is particularly useful for generating and screening for Nsc Abus that remain the binding capabilities to their respective antigens within a cell. The present invention also provides recombinant polynucleotides, host cells and kits comprising the vectors. Further provided by the invention are methods of using the subject vectors.Type: GrantFiled: August 22, 2002Date of Patent: February 20, 2007Inventor: Shengfeng Li
-
Patent number: 7169901Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.Type: GrantFiled: September 3, 2002Date of Patent: January 30, 2007Assignee: Genentech, Inc.Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
-
Patent number: 7151169Abstract: The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralising activity for TGF?1 and are useful in treating conditions associated with excess TGF?1 activity, such as fibrosis, immune responses and tumor progression.Type: GrantFiled: September 13, 2002Date of Patent: December 19, 2006Assignee: Cambridge Antibody Technology LimitedInventors: Julia Elizabeth Thompson, Simon Nicholas Lennard, Alison Jane Wilton, Peta Sally Helena Braddock, Sarah Leila Du Fou, John Gerald McCafferty, Louise Anne Conroy, Philip Ronald Tempest
-
Patent number: 7148321Abstract: Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more than one type of antibody and/or mutant antibody sequences. Hybrid antibody fusion proteins of the invention may be produced at high levels and may combine functional properties characteristic of different antibody types in addition to functional properties of a non-antibody moiety.Type: GrantFiled: March 7, 2002Date of Patent: December 12, 2006Assignee: EMD Lexigen Research Center Corp.Inventors: Stephen D. Gillies, Kin-Ming Lo
-
Patent number: 7148326Abstract: Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.Type: GrantFiled: January 30, 2003Date of Patent: December 12, 2006Assignee: Green Peptide Co., Ltd.Inventor: Kyogo Itoh
-
Patent number: 7132511Abstract: The present invention relates to antibodies which are directed to the EGF receptor (HER1) to be administered especially to humans and in particular for therapeutic use in tumors. The antibodies are modified whereby the modification results in a reduced propensity for the antibody to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of anti-EGFR antibody 425 in its different forms and fragments thereof to result in Mab 425 variants that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used in vivo.Type: GrantFiled: February 18, 2002Date of Patent: November 7, 2006Assignee: Merck Patent GmbHInventors: Francis J. Carr, Graham Carter, Tim Jones, Stephen Williams, Anita Hamilton
-
Patent number: 7129330Abstract: The present invention relates to multivalent Fvantibody construct having at least four variable domains which are linked with each over via the peptide linkers 1, 2 and 3. The invention also concerns expression plasmids which code for such an Fvantibody construct and a method of producing the Fvantibody constructs as well as their use.Type: GrantFiled: May 5, 1999Date of Patent: October 31, 2006Assignee: Deutsches Krebsforschungszentrum Stiftung des Offentlichen RechtsInventors: Melvyn Little, Sergej Kipriyanov
-
Patent number: 7115716Abstract: The invention provides tumor-specific human monoclonal antibodies and functional fragments. Also provided are nucleic acids encoding tumor-specific human monoclonal antibodies and functional fragments. A method for reducing neoplastic cell proliferation is also provided. The method consists of administering an effective amount of a tumor-specific human monoclonal antibody or functional fragment. Also provided is a method of detecting a neoplastic cell in a sample. The method consists of contacting a cell with a tumor-specific monoclonal antibody or functional fragment and detecting the specific binding of the human monoclonal antibody or functional fragment to the sample.Type: GrantFiled: November 19, 2002Date of Patent: October 3, 2006Assignee: Eli Lilly and CompanyInventor: Jeffry D. Watkins
-
Patent number: 7112324Abstract: Described are novel single-chain multifunctional polypeptides comprising at least two binding sites specific for the CD19 and CD3 antigen, respectively. Further provided are polypeptides, wherein the above-described polypeptide comprises at least one further domain, preferably of pre-determined function. Furthermore, polynucleotides encoding said polypeptides as well as to vectors comprising said polynucleotides and host cells transformed therewith and their use in the production of said polypeptides are described, In addition, compositions, preferably pharmaceutical and diagnostic compositions are provided comprising any of the afore-described polypeptides, polynucleotides or vectors. Described is also the use of the afore-mentioned polypeptides, polynucleotides and vectors for the preparation of pharmaceutical compositions for immunotherapy, preferably against B-cell malignancies such as non-Hodgkin lymphoma.Type: GrantFiled: April 21, 1999Date of Patent: September 26, 2006Assignee: Micromet AGInventors: Bernd Dorken, Gert Riethmuller, Peter Kufer, Ralf Lutterbuse, Ralf Bargou, Anja Loffler
-
Patent number: 7060808Abstract: A nucleic acid is provided which encodes a humanized antibody or fragment thereof, which encodes a protein which binds to human EGF-receptor. Monoclonal antibody 225 is the complementary determining region (CDR) donor.Type: GrantFiled: June 7, 1996Date of Patent: June 13, 2006Assignee: ImClone Systems IncorporatedInventors: Neil I. Goldstein, Nicholas A. Giorgio, Steven Tarran Jones, Jose William Saldanha